Please assess the completion status of the following clinical trial:

Trial Title: ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients at least 18 years of age~* Symptoms of OAB for a minimum of 3 consecutive months prior to study entry; severity of OAB (as defined by patient reported symptoms) for a minimum of one month prior to study entry~* Ability to use a toilet independently and without difficulty~* No treatment with any medication against OAB during the 4 weeks prior to study entry~* Written informed consent~Exclusion Criteria:~* Breastfeeding women, pregnant women or women who intend to become pregnant during the study or women of childbearing potential who are sexually active and not practicing a highly reliable method of birth control~* Any local pathology, that might cause the bladder symptoms~* Significant stress urinary incontinence or mixed stress/urgency incontinence~* Any neurological disease affecting bladder function or muscle strength~* Patient history of any lower urinary tract surgery or previous pelvic irradiation~* Local administration of botulinum toxin within the last 9 months in the lower urinary tract~* Start or change of a behavioral bladder training program~* Post voiding residual volumes larger than 250ml or symptoms of clinically relevant bladder outlet obstruction~* Nocturial polyuria~* History of liver disease and/or impaired liver function~* Cholestasis~* Chronic alcohol or drug abuse~* Evidence of significantly impaired renal function (~* Diabetes mellitus (type I or II) with significant peripheral neuropathy and/or polyuria~* Inflammatory bowel disease such as Crohn's disease, or ulcerative colitis~* Uncontrolled narrow angle glaucoma~* Chronic use of carbamazepine or paracetamol~* Participation in any drug study in the preceding 3 months~* Concomitant treatment with strong CYP3A4 inhibitors~* History or evidence of relevant cardiovascular or cerebrovascular disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).